Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -76.12% is 75% above its 5-year average of -300.85%, near the high end of its 5-year range (-1108.34%–-59.66%).
57.06% above its 12-month average of -177.28%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -11.80%.
RETURN ON ASSETS (ROA)
-76.12%
RETURN ON ASSETS (ROA) AVG TTM
-177.28%
RETURN ON ASSETS (ROA) AVG 3Y
-394.98%
RETURN ON ASSETS (ROA) AVG 5Y
-300.85%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+57.06%
CURRENT VS 3Y AVG
+80.73%
CURRENT VS 5Y AVG
+74.70%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-25.07%
median of 450 covered companies
CURRENT VS SECTOR MEDIAN
-203.69%
vs the sector median at left
CNS Pharmaceuticals, Inc.
Market Cap
$7.75M
Return on Assets (ROA)
-76.12%
TTM Avg
-177.28%
3Y Avg
-394.98%
5Y Avg
-300.85%
Market Cap
$7.77M
Return on Assets (ROA)
-381.53%
TTM Avg
-330.40%
3Y Avg
-209.86%
5Y Avg
-253.27%
Market Cap
$7.31M
Return on Assets (ROA)
-414.54%
TTM Avg
-226.50%
3Y Avg
-135.75%
5Y Avg
-126.75%
Market Cap
$8.37M
Return on Assets (ROA)
-29.10%
TTM Avg
-66.56%
3Y Avg
-142.45%
5Y Avg
-115.37%
Market Cap
$7.03M
Return on Assets (ROA)
-206.32%
TTM Avg
-53.14%
3Y Avg
-33.03%
5Y Avg
-33.03%
Market Cap
$6.88M
Return on Assets (ROA)
-283.63%
TTM Avg
-124.17%
3Y Avg
-74.25%
5Y Avg
-35.74%
Market Cap
$6.76M
Return on Assets (ROA)
-97.60%
TTM Avg
-274.34%
3Y Avg
-160.93%
5Y Avg
-165.76%
Market Cap
$6.74M
Return on Assets (ROA)
-50.98%
TTM Avg
-191.11%
3Y Avg
-206.10%
5Y Avg
-240.87%
Market Cap
$8.76M
Return on Assets (ROA)
-6.36%
TTM Avg
-31.97%
3Y Avg
-31.64%
5Y Avg
-61.82%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CNS Pharmaceuticals, Inc. (CNSP) | $7.75M | -76.12% | -177.28% | -394.98% | -300.85% |
| GT Biopharma, Inc. (GTBP)vs › | $7.77M | -381.53% | -330.40% | -209.86% | -253.27% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | -414.54% | -226.50% | -135.75% | -126.75% |
| Aprea Therapeutics, Inc. (APRE)vs › | $8.37M | -29.10% | -66.56% | -142.45% | -115.37% |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.03M | -206.32% | -53.14% | -33.03% | -33.03% |
| Co-Diagnostics, Inc. (CODX)vs › | $6.88M | -283.63% | -124.17% | -74.25% | -35.74% |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.76M | -97.60% | -274.34% | -160.93% | -165.76% |
| Aclarion, Inc. (ACON)vs › | $6.74M | -50.98% | -191.11% | -206.10% | -240.87% |
| Advanced Biomed Inc. Common Stock (ADVB)vs › | $8.76M | -6.36% | -31.97% | -31.64% | -61.82% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.72M | -71.23% | -61.08% | -51.04% | -61.11% |
ROA
-76.1%
ROE
-91.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -183.81% |
| 2024-12-31 | -170.76% |
| 2023-12-31 | -1108.34% |
| 2022-12-31 | -117.02% |
| 2021-12-31 | -165.52% |
| 2020-12-31 | -59.66% |
| 2019-12-31 | -49.00% |
| 2018-12-31 | -1081.74% |
| 2017-12-31 | -324.59% |
